Reduction in Risk Across Fourteen Obesity-Related Cancers A large observational study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, involving more than 170,000 patients with diabetes and obesity, found that GLP-1 receptor agonists were associated with a modest but statistically meaningful reduction in the incidence of 14 obesity-related cancers , with colorectal cancer demonstrating particularly favourable outcomes when compared to patients receiving DPP-4 inhibitors
If you are breastfeeding, newly postpartum, pumping, combo feeding, or starting to wean, you may be hearing about GLP-1 medications everywhere
Kaiser GLP-1 Coverage by Region in 2026 Each region operates somewhat independently, and formulary decisions, copay structures, and prior authorization criteria can differ meaningfully from one region to the next
In its boldest, most high-profile maneuver, Hims capitalized on a temporary regulatory loophole: an FDA-designated shortage of semaglutide, the active ingredient in blockbuster weight loss drugs like Ozempic and Wegovy
Body composition beyond the scale Weight does not distinguish between fat loss and muscle loss
Active Ingredients with a Purpose
.png)
